170 related articles for article (PubMed ID: 10148312)
21. Storage of platelet concentrates from pooled buffy coats made of fresh and overnight-stored whole blood processed on the novel Atreus 2C+ system: in vitro study.
Sandgren P; Callaert M; Shanwell A; Gulliksson H
Transfusion; 2008 Apr; 48(4):688-96. PubMed ID: 18194379
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy-coats: a retrospective analysis of count increment, corrected count increment and transfusion interval.
Cid J; Ramiro L; Escoda L; Llorente A
Vox Sang; 2009 Jan; 96(1):29-33. PubMed ID: 19121195
[TBL] [Abstract][Full Text] [Related]
23. Fully automated processing of buffy-coat-derived pooled platelet concentrates.
Janetzko K; Klüter H; van Waeg G; Eichler H
Transfusion; 2004 Jul; 44(7):1052-8. PubMed ID: 15225247
[TBL] [Abstract][Full Text] [Related]
24. Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation.
Fernández-Muñoz H; Plaza EM; Rivera-Caravaca JM; Candela MJ; Romera M; De Arriba F; Lozano ML; Vicente V; Heras I; Castilla-Llorente C; Rivera J
Hematology; 2018 Oct; 23(9):712-718. PubMed ID: 29582705
[TBL] [Abstract][Full Text] [Related]
25. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
Vasconcelos E; Figueiredo AC; Seghatchian J
Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
[TBL] [Abstract][Full Text] [Related]
26. Differences in levels of platelet-derived microparticles in platelet components prepared using the platelet rich plasma, buffy coat, and apheresis procedures.
Noulsri E; Udomwinijsilp P; Lerdwana S; Chongkolwatana V; Permpikul P
Transfus Apher Sci; 2017 Apr; 56(2):135-140. PubMed ID: 28029568
[TBL] [Abstract][Full Text] [Related]
27. Paired comparison of platelet concentrates prepared from platelet-rich plasma and buffy coats using a new technique with 111In and 51Cr.
Keegan T; Heaton A; Holme S; Owens M; Nelson E; Carmen R
Transfusion; 1992 Feb; 32(2):113-20. PubMed ID: 1542917
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic efficacy of different types of platelet concentrates in thrombocytopenic patients.
Singh RP; Marwaha N; Malhotra P; Dash S
Indian J Hematol Blood Transfus; 2008 Mar; 24(1):16-22. PubMed ID: 23100935
[TBL] [Abstract][Full Text] [Related]
29. [Quality of thrombocyte preparations from buffy coat or platelet-rich plasma].
Bux J; Müller K; Misterek J; Mueller-Eckhardt C
Beitr Infusionsther; 1990; 26():99-102. PubMed ID: 1703912
[TBL] [Abstract][Full Text] [Related]
30. Comparison of blood component preparation methods from whole blood bags based on buffy coat extraction.
Cid J; Claparols M; Pinacho A; Hernández JM; Ortiz P; Puig LS; Pla RP
Transfus Apher Sci; 2007 Jun; 36(3):243-7. PubMed ID: 17569593
[TBL] [Abstract][Full Text] [Related]
31. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.
Akkök CA; Brinch L; Lauritzsen GF; Solheim BG; Kjeldsen-Kragh J
Vox Sang; 2007 Jul; 93(1):42-8. PubMed ID: 17547564
[TBL] [Abstract][Full Text] [Related]
32. Cytoskeletal reorganization after preparation of platelet concentrates, using the buffy coat method, and during their storage.
Estebanell E; Diaz-Ricart M; Lozano M; Mazzara R; Escolar G; Ordinas A
Haematologica; 1998 Feb; 83(2):112-7. PubMed ID: 9549921
[TBL] [Abstract][Full Text] [Related]
33. Platelet concentrates in an additive solution prepared from pooled buffy coats. In vivo studies.
Eriksson L; Shanwell A; Gulliksson H; Högman CF; Svensson LA; Kristensen J; Berg B
Vox Sang; 1993; 64(3):133-8. PubMed ID: 8484245
[TBL] [Abstract][Full Text] [Related]
34. Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation.
Everts PA; Hoffmann J; Weibrich G; Mahoney CB; Schönberger JP; van Zundert A; Knape JT
Transfus Med; 2006 Oct; 16(5):363-8. PubMed ID: 16999760
[TBL] [Abstract][Full Text] [Related]
35. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.
Diedrich B; Ringdén O; Watz E; Shanwell A
Vox Sang; 2009 Oct; 97(3):254-9. PubMed ID: 19508669
[TBL] [Abstract][Full Text] [Related]
36. In-process cell counts during preparation of platelet concentrates from buffy coats.
Stampfli R; Schaller M; Schenker T; Frey-Wettstein M; Hauser SP; Nydegger UE
Transfus Sci; 1997 Dec; 18(4):495-503. PubMed ID: 10178672
[TBL] [Abstract][Full Text] [Related]
37. Transfusion of platelet concentrates--clinical evaluation of two preparations.
Strindberg J; Berlin G
Eur J Haematol; 1996 Oct; 57(4):307-11. PubMed ID: 8982294
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of platelet activation and cytokine release during storage of platelet concentrates processed from buffy coats either manually or by the automated OrbiSac system.
Vetlesen A; Mirlashari MR; Ezligini F; Kjeldsen-Kragh J
Transfusion; 2007 Jan; 47(1):126-32. PubMed ID: 17207241
[TBL] [Abstract][Full Text] [Related]
39. [Preparation of leukocyte-poor thrombocyte concentrates from buffy coat by using a new quadruple bag system].
Misterek J; Müller K; Bux J; Mueller-Eckhardt C
Beitr Infusionsther; 1990; 26():96-8. PubMed ID: 1703911
[TBL] [Abstract][Full Text] [Related]
40. Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients.
Schlenke P; Hagenah W; Irsch J; Sundin D; Corash L; Lin L; Kirchner H; Wagner T
Ann Hematol; 2011 Dec; 90(12):1457-65. PubMed ID: 21503644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
